The merger is on track for the July 24 close and July 16 special meeting. Monitor stockholder vote outcome and any last-minute deal amendments. Post-close, the combined entity (YARW) will be a clinical-stage biotech with Phase 2a GD data as the next major catalyst in 2H 2027.
Price Chart
Executive Summary
VYNE Therapeutics filed an 8-K (Item 7.01) furnishing an investor presentation by Yarrow Bioscience, the merger partner in the pending reverse merger expected to close ~July 24, 2026. The presentation details Yarrow's lead asset YB-101, a potential first-in-class anti-TSHR antibody for Graves' disease and thyroid eye disease, with Phase 2a POC data expected in 2H 2027 and $200M raised to fund operations into 2028. The filing is a routine deal-progression update with no new financial data, but the cross-filing context (prior 425 announcing a special dividend conditioned on merger close) confirms the transaction is on track for the July 24 timeline.
Key Facts
- Reverse merger with Yarrow Bioscience expected to close ~July 24, 2026; combined company to trade on NASDAQ as YARW.
- Yarrow has raised $200M to date (including expected $100M from pre-closing financing) with cash runway into 2028.
- Lead candidate YB-101 (anti-TSHR antibody) has Fast Track Designation from FDA for Graves' disease; Phase 2a/2b GD trial initiated Q2 2026 with POC data expected 2H 2027.
- GenSci Phase 1 SAD in TED showed favorable safety (no SAEs, no hearing/hyperglycemia AEs) and dose-dependent proof of mechanism with 66.7% ORR and proptosis improvement vs 10-20% placebo.
- VYNE declared a special cash dividend of ~$16.5M ($0.38/share) conditioned on merger close per prior 425 filing.
- Estimated post-close ownership: VYNE 3.0%, Yarrow 97.0%, with ~1.43B total shares on as-converted basis.
Financial Impact
No new financial data in this filing. Prior 425 disclosed ~$16.5M special dividend ($0.38/share) conditioned on merger close.
Risk Factors
- Merger may not close if stockholder approval is not obtained at July 16 special meeting.
- YB-101 is in early clinical development; Phase 2a POC data may fail to replicate Phase 1 signals.
- Post-merger dilution is substantial: VYNE shareholders will own only ~3% of the combined company.
- Competing biologics (anti-FcRn, IgG degraders) are also advancing in GD/TED.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (VYNE) — Batch item 1 | 0001104659-26-083359 |
| Document: tm2620382d2_425.htm | 0001104659-26-083356 |
| Document: 0001104659-26-083359-index-headers.html | 0001104659-26-083359 |
| Document: 0001104659-26-083359-index.html | 0001104659-26-083359 |
| Document: 0001104659-26-083359.txt | 0001104659-26-083359 |
| 8-K Filing (VYNE) — Batch item 6 | 0001104659-26-083356 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | SC 13G | — | awaiting T+20 | — | — |
Jul 29, 2026 12w ago | 3 | $28.05 | awaiting T+20 | — | — |
Jul 21, 2026 14w ago | 8-K | $0.8927 | awaiting T+20 | — | — |
Jul 14, 2026 15w ago | 425 / 8-K | $0.7110 | awaiting T+20 | — | — |
Jul 10, 2026 15w ago | 425 / 8-K | $0.6376 | awaiting T+20 | — | — |
Jun 17, 2026 18w ago | EFFECT | $0.6311 $0.7675 | ▲ +21.61% | ▲ +20.30% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers